Free Trial
NASDAQ:POAI

Predictive Oncology (POAI) Stock Price, News & Analysis

Predictive Oncology logo
$0.90 0.00 (0.00%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.90 0.00 (0.00%)
As of 05/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Predictive Oncology Stock (NASDAQ:POAI)

Key Stats

Today's Range
$0.87
$0.93
50-Day Range
$0.87
$1.69
52-Week Range
$0.55
$3.06
Volume
205,555 shs
Average Volume
1.94 million shs
Market Capitalization
$8.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Hold

Company Overview

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

Predictive Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

POAI MarketRank™: 

Predictive Oncology scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Predictive Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Predictive Oncology has received no research coverage in the past 90 days.

  • Read more about Predictive Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Predictive Oncology are expected to grow in the coming year, from ($2.08) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Predictive Oncology is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Predictive Oncology is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Predictive Oncology has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Predictive Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    1.43% of the float of Predictive Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Predictive Oncology has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Predictive Oncology has recently decreased by 37.84%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Predictive Oncology does not currently pay a dividend.

  • Dividend Growth

    Predictive Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.43% of the float of Predictive Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Predictive Oncology has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Predictive Oncology has recently decreased by 37.84%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Predictive Oncology has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Predictive Oncology this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for POAI on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Predictive Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.44% of the stock of Predictive Oncology is held by insiders.

  • Percentage Held by Institutions

    Only 9.04% of the stock of Predictive Oncology is held by institutions.

  • Read more about Predictive Oncology's insider trading history.
Receive POAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter.

POAI Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Headlines

POAI Stock Analysis - Frequently Asked Questions

Predictive Oncology's stock was trading at $0.82 at the beginning of 2025. Since then, POAI stock has increased by 10.4% and is now trading at $0.9050.
View the best growth stocks for 2025 here
.

Predictive Oncology Inc. (NASDAQ:POAI) announced its quarterly earnings data on Wednesday, May, 14th. The medical instruments supplier reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.23. The medical instruments supplier earned $0.11 million during the quarter, compared to analysts' expectations of $1.50 million. Predictive Oncology had a negative net margin of 1,012.32% and a negative trailing twelve-month return on equity of 286.30%.

Predictive Oncology's stock reverse split on the morning of Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Predictive Oncology investors own include Ford Motor (F), Wells Fargo & Company (WFC), Zomedica (ZOM), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Bank of America (BAC) and Wayfair (W).

Company Calendar

Last Earnings
5/14/2025
Today
5/28/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:POAI
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+239.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.98 million
Net Margins
-1,012.32%
Pretax Margin
-983.62%

Debt

Sales & Book Value

Annual Sales
$1.73 million
Price / Cash Flow
N/A
Book Value
$2.04 per share
Price / Book
0.43

Miscellaneous

Free Float
6,438,000
Market Cap
$7.90 million
Optionable
Not Optionable
Beta
1.30

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:POAI) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners